There is no association between benzodiazepine use during pregnancy and increased risk for major congenital malformations.

Pharmacologic interventions for OUD yield varying benefits for treatment retention and abstinence based on type of therapy.

The Food and Drug Administration (FDA) has granted Fast Track designation to AV-1959R for the prevention of Alzheimer disease in cognitively unimpaired individuals with biomarker evidence of amyloid ...

Robert Kauffman, MD, discusses the updated ACOG clinical guidance outlining pharmacologic and nonpharmacologic interventions for menopausal symptoms.

Higher ultraprocessed food intake is associated with greater odds of vascular brain injury and adiposity, but not cognitive performance.

Medical cannabis does not seem to have a clinically meaningful effect on sleep quality or total sleep time among adults with insomnia.

There is a strong association between epilepsy and young-onset dementia, defined as onset of dementia in people aged younger than 65 years.

Initiating pharmacotherapy for attention-deficit/hyperactivity disorder was associated with a reduction in self-harm events, emphasizing the clinical importance of timely intervention.

Psychiatric disorders, such as alcohol use disorder and depression, occurring after a traumatic event significantly increase risk for MACCE.

An increased risk for autism spectrum disorder and intellectual disability appear to be associated with congenital TORCH infections.

New guidelines for menopause treatment focus on hormone therapy and managing symptoms like hot flashes, sleep trouble, and depression.

Women with polyendocrine metabolic ovarian syndrome have an elevated risk for Alzheimer disease driven by metabolic dysfunction.